Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck's Steve Turley re-elected as EMG chair

And Actelion's Robin Bhattacherjee retains vice-chair position

Steve Turley, LundbeckThe European Medicines Group (EMG) has made several senior appointments, re-electing both Lundbeck's Steve Turley as chair and Actelion's Robin Bhattacherjee as vice-chair, and electing Servier's Mike Sumpter as treasurer.

The announcements were made at the annual general meeting of the EGM, which was formed in 2001 to represent UK affiliates of pharma companies headquartered in continental Europe.

Turley (pictured) was originally appointed chair of the Group last year after the departure of Matthew Speers, former managing director of UCB.

Turley has been managing director of Lundbeck's UK operations since 2009 following spells as general manager UK and Ireland at Actelion and business unit director at Roche.

Bhattacherjee took over as vice-chair of the EMG last year, replacing Turley, who he also took over from at Actelion with his 2009 appointment as general manager of the company's UK operations – a position he still holds.

Previously, Bhattacherjee worked at CV Therapeutic Europe as executive director and at Sanofi-Synthelabo as head of cardiovascular marketing. Prior to this, he spent 16 years at Bayer.

Meanwhile, Mike Sumpter has been CEO of Servier's UK business since 2008, a role that was preceded by a spell as CEO of the company's business in Canada.

16th May 2013

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Main image2
Customers, content and change
By Dominic Tyer...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...